Trofex prostate cancer molecular imaging programme to target prostate cancer cells
Monday, 5 January 2009 - Molecular Insight Pharmaceuticals described the synthesis and initial evaluation of two series of radio-labelled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer, in a preclinical study published in the Journal of...
Edited by: Evgenia Starkova
ASCO cites abiraterone as among the notable advances in advanced PCa treatment
Monday, 5 January 2009- The American Society of Clinical Oncology (ASCO) has noted two early studies as among the most promising advances in 2008 in the treatment of advanced or hormone-refractory prostate cancer (PCa).
Issued each year, ASCO’s independent report titled "Clinical Cancer Advances...
Edited by: Joel Vega
Preventing organ rejection in kidney transplant patients using LCP-Tacro enters Phase 3 trial
Friday, 2 January 2009- The Denmark-based LifeCycle Pharma (LCP) has started enrolment of the first patient in it's Phase 3 clinical trial programme for use of LCP-Tacro used to prevent organ rejection in stable kidney transplant patients.
The clinical trial protocol, reviewed by the Unites States’ Food and...
Edited by: JV
Ferring's degarelix gets FDA approval for advanced prostate cancer treatment
Thursday, 1 January 2009- Ferring Pharmaceuticals, USA, received approval from the US Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer.
In a press announcement, Ferring said potential...
Edited by: JV
First patient treated with new UroCool in robot-assisted prostate surgery
Wednesday, 31 December 2008- Cardium Therapeutics and its operating unit InnerCool Therapies announced the enrolment of the first patient in a study of hypothermic radical prostatectomy being conducted by researchers at the University of California, Irvine in the United States.
The patient was cooled with InnerCool's...
Edited by: JV
Simple model predicts patients at risk for Chronic Kidney Disease
Tuesday, 30 December 2008- Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and the University of North Carolina at Chapel Hill in the United States have created a simple eight-point risk factor checklist to simple eight-point risk factor checklist to predict which of their patients might...
Edited: JV
Centralised urological care is the key to an effective service delivery in MDT, Part 2
Monday, 22 December 2008 - In the urologist-led oncology MDT model, cases are referred from the Network MDT to three types of clinic for discussion with the patient, so that treatment options can be discussed with the patient. The following are the clinics and the type of patients they receive:
• Urology clinic :...
Edited by: FGR
Low-income men often diagnosed with advanced prostate cancers, says US study
Tuesday, 30 December 2008- Low-income men are more likely to present with advanced prostate cancers because they don’t receive screening services shown to reduce the diagnosis of later-stage cancers, according to a University of California (UCLA) study.
The study focused on a group of disadvantaged men enrolled in...
Edited by: JV
US study shows RNA interference can facilitate vaccine development
Monday, 29 December 2008- Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases. In the US, a new study opens up an entirely new possibility for this powerful tool: researchers at the University of Georgia have...
Edited by: JV
ENLIGHT study examines HIFU procedure for prostate cancer
Monday, 22 December 2008- EDAP Technomed has launched a phase II/III clinical trial evaluating the effectiveness of a non-invasive medical device designed to target and treat prostate cancer with high-intensity focused ultrasound (HIFU).
The ENLIGHT study is a multi-centre clinical trial evaluating the safety and...
Edited by: JV
